Table 3 Medicationa reported by the GPs in intervention group and control group at T1 and T2 and the medication recommendations of the AMSS
Intervention group (n = 35) | Control group (n = 18) | |||||
|---|---|---|---|---|---|---|
T1 | AMSS | T2 | T1 | AMSSb | T2 | |
Antihistamines | ||||||
Nasal | 2 (6) | 1 (3) | 3 (9) | 0 | 1 (6) | 0 |
Ocular | 2 (6) | 0 | 2 (6) | 1 (6) | 0 | 1 (6) |
Oral | 10 (29) | 20c (57) | 15 (43) | 4 (22) | 7 (39) | 4 (22) |
Corticosteroids | ||||||
Nasal | 9 (26) | 16 (46) | 15 (43) | 3 (17) | 9 (50) | 4 (22) |
Pulmonary | 4 (11) | 5 (14) | 6 (17) | 2 (11) | 2 (11) | 1 (6) |
Oral | 0 | 0 | 0 | 1 (6) | 0 | 1 (6) |
Cutaneous class 1 | 1 (3) | 2 (6) | 1 (3) | 0 | 2 (11) | 0 |
Cutaneous class 2 | 1 (3) | 3 (9) | 1 (3) | 0 | 3 (17) | 0 |
Cutaneous class 3 | 0 | 0 | 0 | 1 (6) | 1 (6) | 1 (6) |
Cutaneous class 4 | 0 | 0 | 0 | 0 | 0 | 0 |
B-sympathicomimetics | ||||||
Short-acting | 7 (20) | 20 (57) | 9 (26) | 3 (17) | 13 (72) | 4 (22) |
Long-acting | 0 | 0 | 1 (3) | 0 | 1 (6) | 0 |
Leukotrien antagonists | 0 | 0 | 0 | 1 (6) | 0 | 1 (6) |
Combination therapy (corticosteroids with B-sympathicomimetics) | 0 | 1 (3) | 1 (3) | 2 (11) | 0 | 2 (11) |
Decongestants | 0 | 0 | 0 | 0 | 0 | 0 |
Emollients | 1 (3) | 7 (20) | 1 (3) | 1 (6) | 5 (28) | 1 (6) |
Epinephrine auto-injector | 0 | 8 (23) | 2 (6) | 0 | 3 (17) | 0 |